$53.01
+0.00 (+0.00%)
SLNO News2 articles
Soleno Halts European Drug Review Following $2.9B Neurocrine Acquisition
Soleno Therapeutics has withdrawn its European marketing application for VIOKAT, a day after agreeing to a $2.9 billion all-cash acquisition by Neurocrine Biosciences. The move halts a regulatory review previously expected to conclude by mid-2026.
Neurocrine Acquires Soleno in $2.9B Deal for Rare Disease Drug Vykat XR
Neurocrine Biosciences will purchase Soleno Therapeutics in a $2.9 billion all-cash transaction, securing the commercial rights to Vykat XR. The deal offers $53 per share to Soleno stockholders.